Prevent preclinical drug development program: preclinical efficacy and intermediate endpoint biomakers (POP: 01/25/2019 -01/24/2024
Ended Awarded Last action
- Contract number
- 75N91019D00022
- Awardee
-
The Institute For Cancer Research UEI FF1XVJMDYVR1 Part of Temple University-Of The Commonwealth System Of Higher Education
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Task orders
- 6 $7,255,309 obligated
Award facts
- Opportunity
-
- PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Biomarker Endpoints, Preclinical Services for Biopharmaceutical Product Development and Manufacturing, and Toxicology and Pharmacology Testing Pre-Solicitation · N01CN7701918 · Posted Apr 19, 2018
- PREVENT Cancer Preclinical Drug Development Program Award Notice · Posted May 7, 2018
- Combined order value
-
- $7,255,309 Current, with exercised options
- $7,877,923 Potential, with all options
- Last date to order 100% complete
- IDV ceiling 10% used
- $74,995,000.00
- Award type
- Multiple award
- Who can order
- Only the awarding agency
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 9 offers Negotiated Proposal / Quote
- Pricing
- Order Dependent (IDV only)
Award details come from SAM.gov/FPDS.
About this IDV
The National Cancer Institute awarded a multiple-award Indefinite Delivery Contract to The Institute For Cancer Research on January 25, 2019, for preclinical drug development and biomarker services supporting the PREVENT Cancer Preclinical Drug Development Program, with a ceiling of $74,995,000 and an ultimate completion date of January 24, 2024.
Work is performed at The Institute For Cancer Research's facility in Philadelphia, Pennsylvania. The Institute is a non-profit subsidiary of Temple University and operates without SBA set-aside designation. The PREVENT program solicitation, posted in April 2018, sought proposals across three technical pools: Preclinical Efficacy and Biomarkers, Preclinical Services for Product Development and Manufacturing, and Preclinical Toxicology and Pharmacology Testing. Up to 20 IDIQs were awarded across the pools, each with a five-year base period and potential five-year option periods. Primary NAICS codes are 541715 and 541712; PSC code is R408. Task orders under this PREVENT vehicle require preclinical drug testing on 50–100 agents annually across 50–150 studies, with individual order ceilings up to $50 million over the contract life.
Recent task orders issued under this IDIQ include a $1,038,958 delivery order (July 10, 2023, completion July 9, 2027) for colorectal cancer prevention research using urolithin A in rodent models; a $1,199,274 order (May 3, 2023, completion May 2, 2027) for preclinical efficacy and biomarker studies on sulforaphane for malignant mesothelioma prevention; a $2,051,148 order (June 15, 2022, completion May 14, 2026) for vaccines against Fusobacterium for colorectal cancer immunoprevention in familial adenomatous polyposis and Lynch syndrome patients; a $1,570,991 order (September 15, 2022, completion June 14, 2026) for preclinical development of a nano-drug formulation for colon cancer prevention; and a $1,237,620 order (May 18, 2022, completion November 17, 2026) for next-generation GP130/IL-6/STAT3 inhibitor research for colitis-associated colorectal cancer prevention.
Task orders
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Additional Work (new agreement, FAR part 6 applies) | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 75N91019D00022?
75N91019D00022 was awarded to The Institute For Cancer Research by National Cancer Institute (National Institutes of Health) on January 25, 2019.
How much is contract 75N91019D00022 worth?
Orders under 75N91019D00022 have obligated $7,255,309. Their combined potential value, with all options, is $7,877,923. 75N91019D00022's own ceiling is $74,995,000.
How many orders have been placed under contract 75N91019D00022?
6 orders have been placed under 75N91019D00022, the latest on July 10, 2023.
Who can order from contract 75N91019D00022?
75N91019D00022 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.
Is contract 75N91019D00022 part of a contract vehicle?
Yes. 75N91019D00022 is part of PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91019D00022 competed?
The extent of competition for 75N91019D00022 was full and open competition. The government received 9 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV